Blue Water Vaccines announced a novel virus-like particle (VLP) vaccine platform from Cincinnati Children's Hospital Medical Center (Cincinnati Children's). The platform utilizes nanoparticle delivery technology that has the potential for broad application in infectious disease vaccines.
The platform leverages norovirus capsid proteins to present foreign antigens for immune enhancement. The Cincinnati Children's researchers from the Division of Infectious Diseases bioengineered nanoparticles and polymers that are easily produced, stable and immunogenic. Developing this technology has the potential to create next-generation broad vaccines for various indications and/or disease strains. Such applications include, among others, rotavirus, influenza, malaria. Blue Water Vaccines has obtained the exclusive, global license to use the novel platform for vaccine discovery, research, and development.
"Blue Water Vaccines is excited to collaborate with the incredible experts at Cincinnati Children's. We look forward to growing our pipeline with the novel platform to pursue the dual norovirus/rotavirus vaccine and to further develop our influenza program," says Joseph Hernandez, CEO of Blue Water Vaccines. "Additionally, we also hope to leverage the platform to further expand our business development initiatives with prospective collaborators that may wish to pursue the development of both individual and adjunct therapeutics based on this unique platform."
Cincinnati Children's investigators Xi Jason Jiang, PhD and Ming Tan, PhD, shared, "We have been working in infectious diseases research for a combined six decades. This milestone represents an important step toward reaching patients in need."
Blue Water Vaccines intends to apply the technology to developing its revolutionary universal vaccine for influenza and a novel, dual vaccine for norovirus and rotavirus.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!